STM JOURNALS

International Journal of
Antibiotics

https://journals.stmjournals.com/ijab

ISSN: 2584-2986
Volume 2, Issue 1, 2025
January–June
DOI (Journal): 10.37591/IJAB

Review IJAB

Antibiotics in the Modern Era: Challenges, Misuse, and the Fight Against Resistance

Satish Kumar Sarankar[1,*], Sushma Somkuwar[2]

Abstract

Overuse and inappropriate use of antibiotics in human medicine, agriculture and environmental pollution. It is one of the biggest public health risks of the 21st century. The discovery of new antibiotics slowdown and the emergence of multidrug-resistant (MDR) microorganisms has highlighted the urgent need to Creative approaches to fighting opposition. This review explores the current challenges in antibiotic use, the factors driving resistance, and the strategies being implemented to address these issues. We examine the role of antibiotics in modern medicine, highlighting their indispensable role in treating infections but also acknowledging the increasing risks associated with their misuse. Unusual trade international travel and the misuse of antibiotics in agriculture. It greatly facilitates the spread of drug-resistant bacteria. The economic and scientific challenges hindering the development of new antibiotics are also discussed, along with emerging approaches to incentivize research and development. Key strategies for combating AMR include improving stewardship practices, implementing regulatory measures and developing alternative treatments such as vaccines, antimicrobial peptides (AMPs) and AI-driven drug discovery. We also review innovative interventions like the use of phage therapy and immune modulators. The article highlights the importance of a multifaceted approach, combining regulatory frameworks, scientific innovation, and global collaboration to mitigate the threat of AMR. Case studies such as Denmark's successful ban on growth promoters and MIT's AI-driven discovery of halicin provide valuable insights into potential solutions. Despite the challenges, promising advancements offer hope for overcoming the AMR crisis, but global cooperation and sustained investment in research are essential for long-term success in combating resistant infections.

Keywords: Antibiotic discovery, antibiotic misuse, antimicrobial resistance (AMR), alternative therapies, antibiotic stewardship, global health, multidrug-resistant bacteria

INTRODUCTION

Antibiotics are considered the most revolutionary medical advance in human history. Since the accidental discovery of penicillin by Alexander Fleming in 1928, antibiotics have played a pivotal role in combating bacterial infections, saving millions of lives globally and dramatically improving life expectancy. Before antibiotics, common infections like pneumonia, tuberculosis and wound infections were often fatal [1, 2]. Their introduction not only revolutionized medical practice but also enabled the development of modern medicine, including complex surgeries, organ transplants and cancer treatments, which rely on effective infection prevention and treatment. Despite their immense contributions, the utility of antibiotics is increasingly at risk. Over the past few decades antimicrobial resistance (AMR) arises from the overuse of antibiotics misuse and poor antibiotic

***Author for Correspondence**
Satish Kumar Sarankar
E-mail: Satish.sarankar@gmail.com

[1]Professor, Faculty of Pharmacy, Mansarovar Global University, Sehore, Madhya Pradesh, India
[2]Associate Professor, School of Pharmacy, LNCT University, Bhopal, Madhya Pradesh, India

Received Date: November 30, 2024
Accepted Date: December 14, 2024
Published Date: December 18, 2024

Citation: Satish Kumar Sarankar, Sushma Somkuwar. Antibiotics in the Modern Era: Challenges, Misuse, and the Fight Against Resistance. International Journal of Antibiotics. 2025; 2(1): 57–70p.

management [3]. This process occurs when bacteria develop powerful defences against the effects of drugs. The implications of this resistance are profound, ranging from prolonged illnesses and increased healthcare costs to higher mortality rates.

AMR has been identified by the World Health Organization (WHO) as one of the top ten threats to public health worldwide. A comprehensive study published in The Lancet in 2022 [4] estimated that nearly 1.3 million deaths worldwide in 2019 were directly attributed to antibiotic-resistant infections. Compounding the issue is the stark inequality in global antibiotic access and usage. In high-income countries, antibiotics are often overprescribed, sometimes for viral infections where they are ineffective. Conversely, in many low- and middle-income countries, lack of access to antibiotics results in untreated infections and preventable deaths. Adding to the complexity is the widespread use of antibiotics in agriculture, which contributes significantly to resistance. Approximately 70% of antibiotics used globally are administered to livestock, often for non-therapeutic purposes like growth promotion, a practice that introduces resistant bacteria into the food chain and environment [5]. The stagnation of new antibiotic development remains another major obstacle. While bacterial resistance evolves rapidly, the pipeline for novel antibiotics has nearly dried up. The high costs and low profitability associated with antibiotic research deter pharmaceutical companies, leaving the medical community reliant on aging drugs. If current trends persist, humanity faces the prospect of entering a “post-antibiotic era,” where minor infections or routine surgeries could once again become life-threatening.

In this review, we aim to explore the multifaceted challenges surrounding antibiotics in the modern era. We will examine the drivers of antibiotic misuse, the global burden of resistance and the socioeconomic factors exacerbating the problem.

Additionally, we have discussed current strategies to mitigate resistance and highlighted innovative approaches and policies that offer hope for the future. The growing crisis demands a coordinated effort from policymakers, healthcare providers, researchers, and the public to preserve the effectiveness of antibiotics for future generations.

The Role of Antibiotics in Medicine and Beyond

Antibiotics have fundamentally shaped the practice of medicine, public health and various sectors beyond healthcare. Their role extends far beyond curing infections, encompassing critical support in medical procedures, livestock farming and even certain industrial applications [6]. Understanding their diverse uses highlights both their importance and the risks posed by their misuse.

The Role of Antibiotics in Modern Medicine

Treatment of Infectious Diseases

Antibiotics are the primary defence against bacterial infections, including pneumonia, tuberculosis, urinary tract infections (UTIs) and sepsis. For example, penicillin and its derivatives have prevented millions of deaths since their discovery. The global incidence of syphilis, a bacterial sexually transmitted infection, was dramatically reduced following the widespread availability of penicillin in the mid-20th century [7]. A notable case is the eradication of yaws, a chronic bacterial infection affecting skin and bones, in several regions. A single dose of azithromycin has proven effective in treating this disease, as demonstrated in a WHO-led campaign in the Pacific islands, significantly reducing its prevalence in endemic areas.

Help During Severe Medical Conditions

Antibiotics are essential in preventing and treating infections associated with medical surgery [8]. For example: Surgeries: Antibiotics are administered prophylactically before procedures like joint replacements and cardiac surgeries to minimize infection risks. In the absence of antibiotics, postoperative infections could complicate recovery or lead to life-threatening sepsis. Cancer treatment: Chemotherapy often weakens the immune system. As a result, patients are at increased risk of infection.

ISSN: 2584-2986

Broad-spectrum antibiotics like cefepime or piperacillin-tazobactam are frequently used to manage febrile neutropenia in cancer patients.

Organ Transplants: Immunosuppressed transplant recipients rely on antibiotics to prevent bacterial infections during recovery.

Management of Chronic Conditions

Certain chronic conditions, such as cystic fibrosis, require long-term antibiotic use to manage recurrent lung infections caused by *Pseudomonas aeruginosa*. This targeted use improves the quality of life for patients while posing unique challenges in managing resistance.

Case Study: The Impact of Antibiotics in Neonatal Sepsis

Neonatal sepsis is a leading cause of death among newborns in low- and middle-income countries (LMICs). A study conducted in Malawi demonstrated that administering gentamicin and ampicillin reduced neonatal mortality by 50%. However, the same study highlighted the growing prevalence of resistant bacterial strains, underscoring the dual role of antibiotics as lifesavers and contributors to resistance [9].

Use of Antibiotics Beyond Medicine

Antibiotics in Agriculture

Agriculture accounts for most of the antibiotic use worldwide, particularly in livestock farming, where antibiotics are employed for growth promotion, disease prevention and the treatment of infections. Sub-therapeutic doses of antibiotics, such as tetracyclines, are commonly administered to animals to promote weight gain, a practice that was widespread in countries like the U.S. until recent regulations. The emergence of antibiotic-resistant pathogens has helped a great deal in this breach. In high-density farming environments, antibiotics are also used prophylactically to prevent bacterial infections, but this practice fosters the proliferation of resistant bacteria that can transfer to humans through the food chain.

Additionally, antibiotics are utilized in veterinary medicine to treat bacterial infections in animals, a necessary but often unregulated practice that increases the risk of resistance [10]. Together, these agricultural practices play a major role in the emergence and spread of antibiotic resistance, emphasizing the urgent need for stricter regulations and more sustainable farming practices.

Antibiotics in Aquaculture

The aquaculture industry heavily relies on antibiotics to prevent infections in farmed fish. For example, salmon farming in Norway has seen a reduction in bacterial infections thanks to vaccines and antibiotic use. However, in countries like Vietnam, unregulated antibiotic use in shrimp and fish farming has led to resistant bacteria contaminating water sources [11].

Environmental Impact of Agricultural Antibiotics

The overuse of antibiotics in farming introduces resistant bacteria and antibiotic residues into soil and water ecosystems. A study in China found high concentrations of antibiotic residues in agricultural runoff, leading to resistance gene transfer among environmental bacteria [12].

Industrial and Scientific Applications

Antibiotics are sometimes used in food preservation, such as treating dairy products to inhibit bacterial growth. While less common today due to regulatory restrictions, these practices persist in some regions, contributing to low-level antibiotic exposure. Antibiotics like streptomycin and kanamycin are widely used in molecular biology research. They help scientists study bacterial gene functions and develop innovative treatments, such as CRISPR-based therapies [13]. However, laboratory misuse of antibiotics can contribute to resistance, particularly in university or industrial research settings.

The Dual-Edged Sword

While antibiotics are indispensable across these domains, their indiscriminate use creates pathways for resistance to emerge and spread. In healthcare, overprescription and incomplete courses of antibiotics contribute to resistant strains. In agriculture, antibiotics in animal feed promote resistance that spreads through food chains. Environmental contamination introduces resistant genes into ecosystems, creating a global crisis.

Case Study: The Spread of Colistin Resistance

Colistin, an antibiotic of last resort, has increased its use in treating bacterial infections in animals. In 2015, researchers in China identified the mcr-1 gene, which confers resistance to colistin and can be transferred between bacteria. This discovery underscored the global risk of unregulated antibiotic use, leading to calls for stricter controls on colistin in agriculture [14].

Challenges in Antibiotic Use

The challenges associated with antibiotic use are multifaceted, encompassing biological, behavioral and systemic factors. While antibiotics have proven indispensable in treating bacterial infections, their widespread misuse and overuse have given rise to critical issues such as resistance, diminished efficacy, and an alarming lack of new antibiotics in development.

Antibiotic Resistance

Antibiotic resistance occurs when bacteria develop defence mechanisms from exposure to drugs [15]. Resistance occurs in many ways, such as:

Genetic mutations: Antibiotics may become ineffective due to unplanned changes to the bacterial DNA, for example, mutations in the bacteria. Mycobacterium TB causes multidrug-resistant (MDR) strains, making TB more difficult to treat.

Spontaneous genetic changes in bacterial DNA may render antibiotics ineffective. The emergence of infection Multidrug resistant (MDR) strains of Mycobacterium tuberculosis has emerged from mutations that make treating tuberculosis more difficult.

Case Study: Carbapenem-Resistant Enterobacterales (CRE)

CRE are a group of bacteria that have developed resistance to carbapenems, a class of antibiotics often used as a last resort. These “superbugs” are responsible for severe hospital-acquired infections. From studies in the United States The death rate for patients infected with CRE is 50% higher than for patients infected with non-resistant strains [16].

Global burden of Resistance

According to the World Health Organization (WHO), antimicrobial resistance (AMR) could kill 10 million people per year by 2050 if no action is taken. The economic impact is equally staggering, with a potential cost of $100 trillion to the global economy.

Overuse and Misuse of Antibiotics

Inappropriate Prescriptions

In many healthcare systems, antibiotics are overprescribed for viral infections, such as colds and influenza, despite their ineffectiveness against viruses. Studies have shown that up to 50% of antibiotic prescriptions written for outpatient use in the United States are unnecessary [17]. In low- and middle-income countries (LMIC), the disease is largely undiagnosed. This trend is intensified by empirical prescribing.

Self-Medication and Accessibility

In LMICs, antibiotics are generally purchased without a prescription. Self-medication leads to incorrect dosing, incomplete courses and inappropriate drug selection [18]. For instance, in India, over 60% of antibiotics are sold without prescriptions, fuelling widespread misuse.

Agricultural Overuse

Globally, about 70% of antibiotics are used in agriculture, often for non-therapeutic purposes such as growth promotion. This practice introduces antibiotics into the food chain and environment, accelerating resistance. A study in China found that tetracycline residues in poultry farms were linked to the emergence of resistant *Escherichia coli* strains [19]. These bacteria were detected in nearby water sources, demonstrating how agricultural misuse can impact broader ecosystems.

Lack of New Antibiotics

The rapid evolution of bacterial resistance has outpaced the development of new antibiotics, with only two new classes of antibiotics approved between 1980 and 2010. This decline is primarily driven by economic and scientific challenges.

Economically, antibiotics are typically prescribed for short durations, making them far less profitable than medications for chronic conditions. Therefore, most drugmakers are reluctant to spend money on antibiotic research and development.

Scientifically, creating antibiotics that effectively target resistant bacteria while avoiding harm to human cells is a highly complex and resource-intensive process, further hindering progress in this critical area.

In 2019, the Pew Charitable Trusts reported that only 41 antibiotics were in development globally, with most being derivatives of existing drugs rather than novel classes. This highlights the stagnation in innovation and the need for alternative therapies [20].

Globalization and the Spread of Resistance

International travel, trade and migration greatly contribute to the spread of drug-resistant bacteria across borders. Tourists traveling to regions with high rates of antibiotic resistance, such as South Asia, often return carrying resistant bacteria like *Klebsiella pneumoniae*, potentially introducing these strains into their home countries.

Similarly, the importation of food, including meat and produce contaminated with antibiotic-resistant bacteria, exposes populations to resistant pathogens, further exacerbating the global spread of antimicrobial resistance. The New Delhi Metallo-beta-lactamase-1 (NDM-1) gene, first identified in an Indian hospital patient in 2008, confers resistance to multiple antibiotics, including carbapenems [21]. Within two years, it had spread to over 70 countries, partly through medical tourism.

Environmental Contamination

Antibiotic residues originating from healthcare facilities, pharmaceutical industries and agricultural practices significantly contaminate soil and water ecosystems. These residues create a selective pressure that promotes the proliferation of resistant bacteria. For instance, a study conducted in Hyderabad, India, revealed extremely high concentrations of antibiotics in wastewater near pharmaceutical manufacturing plants, highlighting the environmental impact of pharmaceutical waste.

Similarly, agricultural runoff from livestock farms, often laden with antibiotics, introduces these drugs into natural ecosystems [22]. This contributes to the development of resistance in environmental bacteria, which can subsequently transfer their resistance genes to human pathogens, amplifying the global threat of antimicrobial resistance.

Challenges in Low-Resource Settings

In LMICs, systemic issues such as lack of diagnostic tools, poor regulation and limited healthcare access exacerbate antibiotic misuse. Patients often resort to traditional healers or unqualified practitioners who prescribe antibiotics indiscriminately. A survey in Nigeria found that 70% of participants used antibiotics without prescriptions, often for conditions like fever or diarrhea [23]. The absence of robust regulatory frameworks allowed this trend to persist, increasing the risk of resistance.

Factors Driving Misuse of Antibiotics

The misuse of antibiotics is a complex global issue driven by a combination of human behavior, systemic gaps and economic pressures. Misuse encompasses overprescription, improper dosing, self-medication and non-therapeutic uses in agriculture and aquaculture. This section delves into the key factors underlying antibiotic misuse, supported by real-world examples and case studies.

Practices in Healthcare

Overprescribing of antibiotics is a leading cause of antibiotic misuse. For viral illnesses such as the common cold or the flu Doctors often prescribe antibiotics even when they are necessary. This occurs due to several reasons:

- *Diagnostic Uncertainty:* In the absence of rapid and accurate diagnostic tools, physicians may prescribe antibiotics "just in case" to cover potential bacterial infections.
- *Patient Expectations:* Patients frequently demand antibiotics, believing them to be a quick fix for any illness. Physicians may yield to these demands to ensure patient satisfaction.
- *Time Constraints:* In busy healthcare settings, especially in low-resource areas, physicians may lack the time to educate patients about why antibiotics are unnecessary [24].

A study conducted in the United States found that nearly 30% of antibiotic prescriptions in outpatient settings were unnecessary, with the highest rates seen in conditions like sinusitis and bronchitis. Similar trends are observed globally, particularly in LMICs where diagnostic resources are scarce. In many countries, particularly those with resource-limited healthcare systems, there are no strict guidelines for antibiotic prescribing. The absence of monitoring mechanisms allows healthcare providers to prescribe antibiotics indiscriminately.

Public Misconceptions and Behavior

- *Antibiotics as a Cure-All:* Many people perceive antibiotics as a universal remedy for any type of illness, including viral infections. This misconception leads to widespread misuse, such as taking antibiotics for fevers, colds, or diarrhea, conditions often caused by non-bacterial pathogens [25].
- *Stopping prematurely:* After not taking antibiotics for the recommended length of time. Patients often stop taking it as soon as they feel better. This practice leaves bacteria partially treated, increasing the likelihood of resistance.
- *Self-Medication:* In countries where antibiotics are easily accessible over the counter, self-medication is rampant. This often results in inappropriate drug selection, incorrect dosing, or incomplete treatment courses.

Example: Antibiotic Use in India

India, the world's largest consumer of antibiotics, exemplifies the dangers of unregulated access. A 2019 study revealed that nearly 50% of the population used antibiotics without a prescription, often for minor illnesses. The lack of awareness about antibiotic resistance exacerbates the problem.

Agricultural Practices

Low doses of antibiotics are administered to animals to accelerate growth and increase meat yield, while healthy animals in overcrowded farms are routinely given antibiotics to prevent bacterial infections. The public's health is seriously threatened by these methods since they greatly contribute to the development of antibiotic-resistant bacteria, which can spread to people through the ingestion of tainted meat or contact with animal waste [26]. About 70% of antibiotics supplied in the United States were used in cattle until the country outlawed the use of medically critical antibiotics for growth promotion in 2017.

Despite the ban, enforcement remains a challenge and similar practices continue in other countries with weaker regulatory frameworks.

The aquaculture industry, particularly in countries like China, Vietnam and Thailand, relies heavily on antibiotics to prevent infections in farmed fish and shellfish. This practice not only introduces resistance into aquatic ecosystems but also contaminates the human food chain. Agricultural antibiotic use leads to environmental contamination. Antibiotic residues in animal waste are often applied to fields as fertilizer or discharged into water sources, spreading resistant bacteria [27].

Socioeconomic and Systemic Issues

- *Lack of Access to Diagnostics:* In many LMICs, the lack of affordable and accessible diagnostic tools forces healthcare providers to prescribe antibiotics empirically, even when they may not be necessary.
- *Economic Pressures:* Farmers, particularly in low-income settings, use antibiotics as an economic tool to maximize productivity and profits.
- Similarly, healthcare providers may overprescribe antibiotics to meet patient expectations or compete with other practitioners.
- *Inefficient Healthcare Systems:* Inadequate healthcare infrastructure, such as poorly regulated pharmacies and a shortage of trained healthcare professionals, contributes to the misuse of antibiotics. Patients often turn to unlicensed medical professionals who are not well trained in administering antibiotics [28].

In sub-Saharan Africa, a large proportion of the population relies on informal healthcare providers who frequently prescribe antibiotics without proper diagnosis. A study in Uganda found that 80% of patients treated by informal providers received antibiotics, often unnecessarily.

Lack of Awareness and Education

- *Limited Public Awareness:* Public awareness initiatives regarding the risks of antibiotic abuse are inadequate in many parts of the world. The general population frequently does not comprehend how resistance arises or why it is so important to finish recommended courses.
- *Education of Healthcare Providers:* It is possible that even healthcare professionals are undertrained on antibiotic stewardship. This disparity results in inappropriate prescription practices, particularly in underserved or rural communities [29].

Sweden has successfully reduced antibiotic consumption through extensive public awareness campaigns. Programs like "Strama" have educated citizens and healthcare providers about the risks of resistance, resulting in a 43% reduction in antibiotic use over two decades [30].

Pharmaceutical Practices

The overproduction and aggressive marketing of antibiotics by pharmaceutical companies contribute significantly to their overuse and misuse, particularly in low- and middle-income countries (LMICs) where regulatory frameworks are often weaker. In these regions, companies frequently produce large quantities of antibiotics and promote them heavily, creating a culture of dependency and improper use. For example, in countries like Vietnam and Indonesia, antibiotics are readily available in markets and pharmacies without the need for a prescription. This unrestricted access encourages misuse, such as self-medication or inappropriate dosing, further fuelling the development and spread of antibiotic resistance [31].

Current Strategies to Combat Resistance

Governments, healthcare organizations, researchers other stakeholders have implemented various strategies aimed at combating resistance. These strategies focus on prevention, regulation, innovation, education and international collaboration, each with a distinct rationale to reduce resistance and preserve the efficacy of existing antibiotics.

Antibiotic Stewardship Programs (ASPs)

These initiatives aim to maximize the use of antibiotics to improve patient outcomes, reduce drug resistance and save on treatment costs. These programs place great emphasis on prescribing the right antibiotics for the right amount of time [32].

Key Components

1. *Guidelines and Protocols:* Development of evidence-based guidelines to ensure appropriate prescribing.
2. *Education and Training:* Training healthcare providers on proper antibiotic use and resistance mechanisms.
3. *Audit and Feedback:* Regular audits of prescribing practices with constructive feedback to clinicians.

The U.S. Centers for Disease Control and Prevention (CDC) initiated a nationwide ASP program in hospitals, resulting in a 13% decrease in antibiotic use between 2011 and 2020. Hospitals with active ASPs also reported a significant reduction in hospital-acquired infections caused by resistant bacteria.

Controlling the Use of Antibiotics in Agriculture

Excessive use of antibiotics in agriculture contributes to antimicrobial resistance (AMR) by promoting the growth of resistant bacteria in animals. These drug-resistant bacteria pose a serious threat to public health. Because it can spread to people through contact with food. contaminated water or environment. Regulating antibiotic use in agriculture is essential to mitigating this threat. Key measures to address this issue include banning the use of medically important antibiotics as growth promoters in livestock, ensuring veterinary oversight to make antibiotics available only through prescriptions and implementing robust monitoring and surveillance systems to track antibiotic usage and resistance trends in agricultural settings [33].

A compelling example is Denmark’s ban on antibiotic growth promoters in 1999. Following this policy change, studies reported a 50% reduction in antibiotic use in livestock without negatively impacting productivity.

Additionally, resistance levels in bacteria associated with animals significantly declined. Denmark’s success illustrates the effectiveness of well-enforced regulatory measures in curbing antibiotic misuse in agriculture and reducing the spread of resistance.

Strengthening Surveillance Systems

Surveillance helps identify resistance trends, track the spread of resistant pathogens and guide targeted interventions. It also provides essential data for policymaking and global collaboration.

Key Initiatives

1. *Global Antimicrobial Resistance Surveillance System (GLASS):* Launched by the WHO, GLASS collects and analyzes data on AMR globally to guide policy decisions [34].
2. *National Action Plans:* Many countries have developed surveillance programs to monitor resistance at the local level.
3. Thailand’s national AMR surveillance program integrates data from hospitals, laboratories and agricultural sectors. The project’s critical approach to counterproductive trends results in more successful public health initiatives.

Antibiotic Research and Development (R&D)

Creating new antibiotics is essential in the fight against increasing drug resistance**.** However, the pipeline for new antibiotic classes has slowed due to significant economic and scientific challenges. To overcome these obstacles, innovative incentives and collaborative research models are essential to stimulate antibiotic research and development. Key strategies to address these challenges include push incentives, pull incentives and collaborative efforts such as grants and subsidies, aim to reduce the financial burden associated with early-stage research and development, reward successful antibiotic development through mechanisms like market entry rewards or guaranteed purchase agreements, ensuring financial returns for pharmaceutical companies.

Additionally, collaborative research models that involve partnerships between governments, academic institutions and private companies help to pool resources, expertise and knowledge, fostering innovation in antibiotic R&D [35].

Biopharmaceutical Accelerator for Antibiotic Resistant Bacteria (CARB-X), which funds early-stage antibiotic research. It is a well-known example of this type of cooperation. Since its inception, CARB-X has funded over 50 innovative projects, several of which have advanced to clinical trials. This program offers the promise of creating new treatments. powerful to address global health concerns It highlights how thoughtful funding and collaboration can spur progress in the fight against antibiotic resistance [36].

Vaccination and Infection Prevention

Vaccines and infection prevention strategies play a critical role in reducing the incidence of bacterial infections, thereby lowering the demand for antibiotics and slowing the development of resistance. Expanding access to vaccines, such as those against *Streptococcus pneumoniae* (pneumococcus) and *Haemophilus influenzae* type b (Hib), helps prevent bacterial infections that often require antibiotic treatment.

Additionally, promoting hygiene and sanitation measures, including handwashing, access to clean water and rigorous hospital infection control practices, further reduces infection rates. The introduction of pneumococcal conjugate vaccines (PCVs) has had a profound impact, significantly reducing antibiotic use in children by preventing bacterial pneumonia and other pneumococcal infections [37]. For example, a study in the United States reported a 20% decline in antibiotic prescriptions for children under five years of age following the widespread adoption of PCVs, highlighting the effectiveness of such preventive measures.

Public Education Campaigns

Educating the public about the dangers of antibiotic misuse empowers individuals to use antibiotics responsibly, reducing self-medication and demand for unnecessary prescriptions.

Key Initiatives

1. *Global Awareness Campaigns:* WHO’s World Antibiotic Awareness Week promotes responsible antibiotic use through community engagement and media outreach [38].
2. *Behavioral Change Programs:* Localized efforts to change attitudes and practices related to antibiotic use.

AMR and the importance of discontinuing treatment with prescribed antibiotics were the focus of a 2017 UK public awareness campaign. Surveys showed increased awareness and a measurable decline in inappropriate antibiotic requests.

Alternative Therapies

With resistance limiting the effectiveness of traditional antibiotics, alternative therapies provide new avenues for treatment and prevention. Key alternatives include:

1. *Phage Therapy:* Using bacteriophages (viruses that infect bacteria) to target resistant pathogens [39].
2. *Antimicrobial Peptides:* Small molecules that disrupt bacterial membranes.
3. *CRISPR Therapy:* A gene editing technique to inactivate bacterial resistance genes.

In 2019, a critically ill patient in the U.S. with a multidrug-resistant *Acinetobacter baumannii* infection was successfully treated using a personalized phage therapy, demonstrating the potential of this approach (Table 1).

Table 1. Overview of Antibiotics, Their Uses and Resistance Challenges.

Antibiotic Class	Specific Antibiotics	Primary Use	Resistant Pathogens	Resistance Mechanisms	Clinical Implications
Beta-lactams	Penicillin, Amoxicillin	Gram-positive infections (*Streptococcus*)	*Streptococcus pneumoniae, MRSA*	Beta-lactamase production, altered PBPs	Treatment failure in pneumonia, endocarditis
	Carbapenems (Meropenem)	Severe infections, last-resort therapy	*Klebsiella pneumoniae, Pseudomonas*	Carbapenemases (e.g., KPC, NDM)	Limited options for multidrug-resistant Gram-negative bacteria
Cephalosporins	Ceftriaxone, Cefepime	Respiratory, urinary, and bloodstream infections	*Escherichia coli, Klebsiella*	Extended-spectrum beta-lactamases (ESBLs)	Resistance in UTIs and sepsis
Fluoroquinolones	Ciprofloxacin, Levofloxacin	Respiratory and urinary infections	*E. coli, Pseudomonas aeruginosa*	Efflux pumps, target site mutations (gyrA/parC)	Reduced efficacy in UTIs, pneumonia
Aminoglycosides	Gentamicin, Amikacin	Severe Gram-negative infections	*Enterococcus, Klebsiella*	Enzymatic modification of drug, efflux pumps	Limited efficacy in combination therapies
Macrolides	Azithromycin, Erythromycin	Respiratory tract infections	*Streptococcus pneumoniae, H. pylori*	Efflux pumps, methylation of ribosomal targets	Resistance in pneumonia and H. pylori eradication
Tetracyclines	Doxycycline, Minocycline	Acne, respiratory, and zoonotic infections	*Acinetobacter baumannii, E. coli*	Efflux pumps, ribosomal protection proteins	Reduced options in zoonotic and hospital-acquired infections
Glycopeptides	Vancomycin	MRSA, severe Gram-positive infections	*Enterococcus faecium* (*VRE*)	Alteration of peptidoglycan precursors	Treatment failure in endocarditis and bloodstream infections
Sulfonamides	Trimethoprim-sulfamethoxazole	UTIs, opportunistic infections	*E. coli, Pneumocystis jirovecii*	Overproduction of target enzyme (DHFR)	Resistance in UTIs and opportunistic infections in HIV
Polymyxins	Colistin	MDR Gram-negative infections	*Acinetobacter baumannii, Klebsiella*	mcr genes (plasmid-mediated resistance)	Limited last-resort treatment options
Oxazolidinones	Linezolid	MRSA, VRE, resistant Gram-positive infections	*Enterococcus, Staphylococcus aureus*	Mutations in ribosomal RNA	Emerging resistance in nosocomial infections
Rifamycins	Rifampin	Tuberculosis, leprosy	*Mycobacterium tuberculosis*	Mutations in RNA polymerase	Multi-drug-resistant tuberculosis (MDR-TB)

Note: MRSA: Methicillin-resistant Staphylococcus aureus; VRE: Vancomycin-resistant Enterococcus; ESBLs: Extended-spectrum beta-lactamases, enzymes that degrade cephalosporins and penicillins; MDR: Multidrug-resistant.

Emerging Innovations and Future Directions

As the threat of antimicrobial resistance (AMR) intensifies, innovation and forward-thinking strategies are essential to outpace the growing crisis. Emerging technologies, alternative therapies and global partnerships offer new hope in the fight against AMR [40]. This section explores promising innovations and future directions that could reshape how we combat resistance, alongside their underlying rationale and potential impact.

Development of Next-Generation Antibiotics

The rapid evolution of resistant bacteria necessitates antibiotics with novel mechanisms of action that can circumvent existing resistance pathways. Traditional antibiotics often target a narrow range of bacterial functions, making them vulnerable to resistance. Next-generation antibiotics aim to overcome these limitations.

Key Advances May Include

1. *Non-Traditional Targets:* Exploring new bacterial functions, such as virulence factors or quorum sensing, to disable pathogens without directly killing them.
2. *Dual-Action Antibiotics:* Drugs that combine bacterial killing with resistance-suppression mechanisms.
3. *Synthetic Biology:* Designing entirely new antibiotic molecules using advanced bioengineering techniques.

CASE STUDY: TEIXOBACTIN

Discovered in 2015, teixobactin represents a promising class of antibiotics that target bacterial cell wall synthesis in a way that minimizes resistance. Preclinical trials show efficacy against resistant *Staphylococcus aureus* and *Mycobacterium tuberculosis* [41].

Phage Therapy and Its Advancements

Phage therapy, which uses bacteriophages (viruses that infect bacteria) to target and kill specific pathogens, offers a precision tool to combat resistant infections. Unlike antibiotics, phages evolve alongside bacteria, potentially reducing the risk of resistance [42].

KEY INNOVATIONS

1. Phage engineering is the process of genetically modifying phages to increase their efficiency and selectivity against drug-resistant bacteria.
2. *Combination Therapies:* Pairing phages with antibiotics to achieve synergistic effects.
3. *Phage Banks:* Creating repositories of phages tailored to treat a broad range of infections.

CASE STUDY: PHAGE THERAPY IN CYSTIC FIBROSIS

In 2019, a patient with cystic fibrosis in the UK was successfully treated with phage therapy for a *Mycobacterium abscessus* infection resistant to all antibiotics. The promise of phage therapy for multidrug-resistant (MDR) disease is illustrated by this example.

CRISPR-based antimicrobials: Precise gene editing made possible by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. When applied to bacteria, CRISPR-based tools can selectively target and disable resistance genes or kill specific pathogens, leaving beneficial microbiota unharmed [43].

This can be applied for:

1. *Targeting Resistance Genes:* Delivering CRISPR payloads to bacterial populations to eliminate resistance plasmids.
2. Creating a CRISPR system to target a specific strain or strain of bacteria is called “programmable killing.”
3. *Microbiome-Safe Treatments:* Avoiding collateral damage to healthy bacteria, unlike broad-spectrum antibiotics.

Recent studies have demonstrated CRISPR’s potential to eradicate *Escherichia coli* carrying resistance genes in vitro and in animal models, paving the way for clinical applications.

Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are naturally occurring molecules that disrupt bacterial membranes, offering a unique mechanism of action distinct from traditional antibiotics. These molecules hold great promise in combating multidrug-resistant (MDR) bacteria, biofilms and fungi, addressing some of the most challenging aspects of antimicrobial resistance. Recent advances in AMP research have focused on synthetic AMPs, broad-spectrum activity and biofilm penetration. Synthetic AMPs are engineered to enhance their stability, specificity, and therapeutic efficacy, overcoming limitations of natural peptides. The development of broad-spectrum AMPs has led to compounds that can target a wide range of infections. Some of which are resistant to common antibiotics [44].

Additionally, biofilm-penetrating AMPs are being designed to disrupt the protective biofilm matrix that shields bacteria in chronic infections, a major obstacle in current antimicrobial therapies.

One notable example is the clinical trials of AMPs like surotomycin, which has demonstrated potential against *Clostridioides difficile* infections. These trials highlight the ability of AMPs to serve as effective alternatives to existing therapies, particularly for infections where resistance has rendered conventional antibiotics less effective.

Artificial Intelligence (AI) in Antibiotic Discovery

Traditional antibiotic discovery is often hindered by its time-consuming and costly nature. This method is being revolutionized by artificial intelligence (AI), which analyses large data sets to find potential drug candidates and more accurately predict effectiveness. Drug repurposing involves finding new antimicrobial uses for existing drugs, offering a faster route to combating resistant infections. Novel molecule discovery leverages AI to screen extensive chemical libraries and identify compounds with potential antimicrobial properties.

Additionally, resistance prediction utilizes AI to model bacterial evolution, helping to predict resistance mechanisms and guide the design of more robust drugs.

A landmark example of AI's impact came in 2020 when researchers at MIT used AI algorithms to discover halicin, a novel antibiotic. Halicin demonstrated effectiveness against a wide range of resistant bacteria, including carbapenem-resistant *Enterobacteriaceae*, underscoring AI's potential to address the growing crisis of antibiotic resistance [45].

CONCLUSIONS

The global crisis of antimicrobial resistance (AMR) presents a daunting challenge to public health, agriculture and the environment. When it was touted as a miracle drug Antibiotics become less effective because of overprescribing. Widespread misuse and the unchecked development of drug resistance This alarming trend threatens to undermine decades of medical progress, risking a future where routine infections become deadly and complex medical procedures are no longer feasible. Through this review, we have explored the multifaceted nature of antibiotics, their indispensable role in modern medicine and the severe challenges arising from resistance. This problem is made worse by elements such as financial pressures. Inadequate laws and lack of knowledge All parties involved Whether it is the government sector Healthcare providers, businesses and individuals need to work together to solve these problems.

Current strategies to combat resistance emphasize prevention, innovation and collaboration. Antibiotic stewardship programs, stricter regulations on antibiotic use and enhanced surveillance systems have proven effective in mitigating misuse and resistance. Advances in diagnostics, the development of next-generation antibiotics and alternative therapies like phage therapy and CRISPR-based antimicrobials offer hope for the future. Furthermore, global initiatives such as the WHO's Global Action Plan and the One Health approach demonstrate the importance of coordinated, multi-sectoral efforts to address AMR.

REFERENCES

1. Adedeji WA. The treasure called antibiotics. Annals of Ibadan Postgraduate Medicine, 2016; 14(2):56–57.

2. Terico AT, Gallagher JC. Beta-lactam hypersensitivity and cross-reactivity. PharmPrac. 2014; 27(6):530–544.
3. Bailey JK, Pinyon JL, Anantham S, Hall RM. Commensal Escherichia coli of healthy humans: A reservoir for antibiotic-resistance determinants. J MediMicrobio. 2010;59(11):1331–1339.
4. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet. 2022;399(10325):629–655.
5. Llor C, BjerrumL. 2014Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety. 2014;5(6):229–241.
6. Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. The Lancet. 2019;394(10196):420–431.
7. Kinch MS, Patridge E, Plummer M, Hoyer D. An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discovery Today. 2014;19(9):1283–1287.
8. National Collaborating Centre for Women's and Children's Health (UK).Surgical site infection: Prevention and treatment of surgical site infection. London: RCOG Press; 2023.
9. Rudd KE, Johnson SC, Agesa KM. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. The Lancet. 2020;395*(*10219):200–211.
10. Williams-Nguyen J, Sallach JB, Bartelt-Hunt S, Boxall AB, Durso LM, McLain JE, et al. Antibiotics and antibiotic resistance in agroecosystems: State of the science. J Environ Qua. 2016;45(2):394–406.
11. Milić N, Milanovic M, Letić NG, Sekulić MT, Radonić J, Mihajlović I, et al. Occurrence of antibiotics as emerging contaminant substances in the aquatic environment. Int J Environ Health Res. 2013;23(4):296–310.
12. Zhao L, Dong YH, Wang H. Residues of veterinary antibiotics in manures from feedlot livestock in eight provinces of China. Sci the Total Environ. 2010;408(5):1069–1075.
13. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Sci. 2013;339(6121):819–823.
14. Liu YY, Wang Y, Walsh TR. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. The Lancet Infectious Dis. 2016;16(2):161–168.
15. Brauner A, Fridman O, Gefen O. Balaban NQ. Distinguishing between resistance, tolerance, and persistence to antibiotic treatment. Nature Reviews Microbiol. 2016;14(5):320–330.
16. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae *and other* Enterobacteriaceae: An evolving crisis of global dimensions. Clinic Microbiol Rev. 2012;25*(*4):682–707.
17. Carrasco-Garrido P, Jiménez-García R, Barrera V, Gil de Miguel A. Predictive factors of self-medicated drug use among the Spanish adult population. Pharmacoepidemiology and Drug Safety. 2008;17(2):193–199.
18. Borg M, Sciclunca E. Over-the-counter acquisition of antibiotics in the Maltese general population. Int J Antimicro Agents. 2002;20(3):253–257.
19. Rasheed MU, Thajuddin N, Ahamed P, Teklemariam Z, Jamil K. Antimicrobial drug resistance in strains of Escherichia coli isolated from food sources. Revista do Instituto de Medicina Tropical de São Paulo. 2014;56(4):341–346.
20. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet. 2022;399(10325):629–655.
21. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): Towards a new pandemia? Clinic Microbiol Infect. 2010;16(12):1699–1701.
22. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicro Agents and Chemothera. 2011;55(3):1274–1278.

23. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay A. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. BMJ. 340, c2096.2010.
24. Coenen S, Francis N, Kelly M, Hood K, Nuttall J, Little P. Are patient views about antibiotics related to clinician perceptions, management, and outcome? A multi-country study in outpatients with acute cough. PLoS ONE. 2013;8(10):e76691.
25. Singh R, Yadav AS, Tripathi V, Singh RP.Antimicrobial resistance profile of Salmonella present in poultry and poultry environment in north India. Food Control. 2013;33(2):545–548.
26. Food Safety and Standards Authority of India. Fixation of maximum residue levels for pesticides, veterinary drugs, and antibiotics in foods prepared from animals, poultry, fish, and processed foods. FSSAI Workshop; 2016.
27. Mellon M, Benbrook C, Benbrook KL. Hogging it: Estimates of antibiotic abuse in livestock. UCS Publications; 2001.
28. Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance, and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14(5):320–330.
29. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrobial Resistance & Infection Control. 2017;6:47.
30. Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. The Lancet Infect Dis. 2008;8(2):125–132.
31. Stålsby Lundborg C,Tamhankar AJ. Understanding and changing human behaviour: Antibiotic mainstreaming as an approach to facilitate modification of provider and consumer behaviour. Upsala J Med Sci. 2014;119(2):125–133.
32. Hanberger H, Skoog G, Ternhag A, Giske CG. Antibiotic consumption and antibiotic stewardship in Swedish hospitals. Upsala J Med Sci. 2014;119(2):154–161.
33. Bhushan C, Khurana A, Sinha, Nagaraju M. Antibiotic resistance in poultry environment: Spread of resistance from poultry farm to agricultural field. Centre for Sciand Environ. 2017.
34. World Health Organization. The Global Antimicrobial Resistance Surveillance System; 2015.
35. So AD, Shah TA. New business models for antibiotic innovation. Upsala J Med Sci. 2014;119(2):176–180.
36. Nadimpalli M, Delarocque-Astagneau E, Love DC, Price LB, Huynh BT, Collard JM. Combating global antibiotic resistance: Emerging One Health concerns in lower- and middle-income countries. Clin Infecti Di. 2018;66(6):963–969.
37. Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proce the Nat Aca Sci of the United States of America. 2018; 115(51):12896–12901.
38. World Health Organization. Global action plan on antimicrobial resistance; 2015.
39. Chanishvili N. Phage therapy: History from Twort and d'Herelle through Soviet experience to current approaches. Advance Virus Res. 2012;83:3–40.
40. Yoshikawa TT. Antimicrobial resistance and aging: Beginning of the end of the antibiotic era? J the Am Geria Soc. 2002;50(Suppl):S226–S229.
41. Ng V, Kuehne SA, Chan WC. Rational design and synthesis of modified teixobactin analogues: In vitro antibacterial activity against Staphylococcus aureus, Propionibacterium acnes, *and* Pseudomonas aeruginosa. Chemistry – A European Journal. 2018;24(36):9136–9147.
42. Motlagh AM, Bhattacharjee AS, Goel R. Biofilm control with natural and genetically modified phages. World J Microbioand Biotechnol. 2016;32(67).
43. Rodrigues M, Mc Bride S, Hullahalli K, Palmer K, Duerkop BA. Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant Enterococci. Antimicrobial Agents and Chemother. 2019;63(11):e01454–19.
44. Zhong C, Zhu N, ZhuY, Liu T, Gou S, Xie J. Antimicrobial peptides conjugated with fatty acids on the side chain of D-amino acid promises antimicrobial potency against multidrug-resistant bacteria. Euro J Pharmaceuti Sci. 2020;141:105123.
45. Wong F, Zheng EJ, Valeri JA. Discovery of a structural class of antibiotics with explainable deep learning. Nature. 2023.

